Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct ...

Guillain-?Barr Syndrome is a rare condition in which a person's immune system attacks the peripheral nerves. People affected suffer from muscle weakness and paralysis. A research team led by ETH ...

Guillain-Barré Syndrome (GBS) is a rare neuromuscular condition that can cause rapid paralysis. Diagnosing GBS is challenging, and misdiagnosis can lead to delayed treatment and potentially long-term ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that attack ...

Annexon (ANNX) announced topline results from a real-world evidence study supporting ANX005 as a potential treatment for Guillain-Barre Syndrome. GBS is a rapid-onset and acute neuromuscular disease ...

Annexon, Inc. (ANNX) was able to achieve positive results from its phase 3 study for the treatment of patients with Guillain-Barré syndrome [GBS]. Matter of fact, it noted that a lower dose of its ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another effort to improve treatment of the rare condition. Alongside a clinical data ...

Patients with Guillain- Barré syndrome (GBS) face a rare and heterogeneous disorder of the peripheral nervous system that is often triggered by preceding infections and causes severe muscle weakness.